‘BBB’ long-term issuer credit rating from S&P Global Ratings
Positive outlook, reflecting expected profitability improvement, ramp up of Nemluvio, and continued deleveraging and balance sheet improvement
Recognition of Galderma’s science-based dermatology portfolio and global operations
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook.
The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation.
S&P highlights momentum from recent launches, including Nemluvio® (nemolizumab), alongside improving profitability and expanding free operating cash flow. The agency also notes Galderma’s disciplined financial policy, supporting expectations of continued deleveraging over the coming years.
The positive outlook indicates that an upgrade could be considered over the next 12–24 months subject to Galderma continuing to deliver profitable growth and maintaining credit-supportive metrics.
Galderma is also rated BBB (stable outlook) by Fitch.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Forward-looking statements
Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.
-
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global RatingsGalderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BB2025-12-06
-
NTT DATA Announces Six New AI-Powered Cyber Defense Centers to Strengthen Cyber Resilience and CountNTT DATA, a global leader in AI, digital business and technology services, today announced the launch of four next-generation autonomous Cyber Defens2025-12-06
-
2026 ChinaBio® 生物医药产业国际合作大会内容亮点与首批演讲企业阵容揭晓, 与1000+创新药专家共启全球合作新纪元在维也纳举行的Bio-Europe刚刚落幕,全球生物医药合作的聚光灯已转向上海。以“开创全球创新和商业合作的新纪元”为主题,2026 ChinaBio® Partnering Forum生物医药2025-12-06
-
解码金锣新战略:以“四化”精准破局,引领健康食代新风向当健康饮食从“加分项”变为“必选项”,传统肉制品企业正站在转型的十字路口。面对“健康中国”的时代考题,金锣集团率先交出答卷。它敏锐捕捉市场脉搏,独创“四2025-12-06
-
Visa推出全球艺术收藏项目,赋能创作者并致敬2026年国际足联世界杯Visa今日揭晓其首个全球艺术收藏项目的首批五件作品,以此致敬2026年国际足联世界杯(FIFA World Cup 26™)所蕴含的文化活力。该收藏项目汇集了来自六大洲的20余位2025-12-06
